glp 1 receptor agonists effects on cardiovascular risk reduction and Tolerability of GLP-1 Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients GLP-1 Agonists in Cardiovascular Diseases:
Description
The comparison between GLP-1RA and SGLT-2 inhibitors shows no difference in their risk for total death (RR = 1.00, 95% CI 0.911.11)
Although diabetic patients and individuals with vascular disease face a higher baseline risk, anyone experiencing sudden changes in vision should seek immediate medical attention to protect their eye health and identify potential underlying conditions affecting the body
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)
X., et al., Body Weight Management in Overweight and Obese Breast Cancer Survivors, Cochrane Database of Systematic Reviews 12 (2020): Cd012110
